Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

1 terminated/withdrawn out of 2 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT06139796Phase 1Withdrawn

Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV

Role: collaborator

NCT06873633Phase 2Recruiting

Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV

Role: collaborator

All 2 trials loaded